In a ginormous new study, researchers have begun mapping the manifold health benefits of drugs like Ozempic and Wegovy beyond weight loss.

Some outcomes, like reduced risk of cardiovascular disease and increased chance of nausea, were expected. But others took researchers by surprise.

The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger.

People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.

Recent findings indicate that widely used weight-loss medications might lead to muscle loss, including vital heart muscle, potentially leading to serious health complications over time. Experts call for more research and a cautious approach to using these drugs,

In one corner, we’ve got Mounjaro, and in the other, Ozempic. They’re both once-a-week injectable drugs designed to help patients with type 2 diabetes manage blood sugar.

Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.

A major new study has revealed a long list of benefits and some little-known risks of Ozempic and other GLP-1 medications. Experts break down the findings.